[
  {
    "ts": "2025-10-17T20:21:54+00:00",
    "headline": "The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly.",
    "summary": "Biotech stocks Disc Medicine and Revolution Medicines jumped Friday after the duo received some of the first CNPVs.",
    "url": "https://www.investors.com/news/technology/biotech-stocks-disc-medicine-revolution-medicines-cnpv/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "ba86d464-e3e5-3bda-9664-bb6ad38b12ee",
      "content": {
        "id": "ba86d464-e3e5-3bda-9664-bb6ad38b12ee",
        "contentType": "STORY",
        "title": "The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly.",
        "description": "",
        "summary": "Biotech stocks Disc Medicine and Revolution Medicines jumped Friday after the duo received some of the first CNPVs.",
        "pubDate": "2025-10-17T20:21:54Z",
        "displayTime": "2025-10-17T20:21:54Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ba86d464-e3e5-3bda-9664-bb6ad38b12ee/the-fda-just-granted-its.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/c0fb77c27ea4e241879b0c3f450366fb",
          "originalWidth": 1000,
          "originalHeight": 565,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fRnc9LtrZO1SIIgSMayQvQ--~B/aD01NjU7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/c0fb77c27ea4e241879b0c3f450366fb.cf.webp",
              "width": 1000,
              "height": 565,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/adAb.KWvgqjVz8XXBhgdaQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/c0fb77c27ea4e241879b0c3f450366fb.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/biotech-stocks-disc-medicine-revolution-medicines-cnpv/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RVMDW"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "IRON"
            },
            {
              "symbol": "RVMD"
            },
            {
              "symbol": "XBI"
            },
            {
              "symbol": "ACHV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-17T18:41:47+00:00",
    "headline": "Is FDA and EMA Progress for Libtayo Transforming the Investment Story for Regeneron (REGN)?",
    "summary": "Regeneron Pharmaceuticals recently received U.S. FDA approval and a positive opinion from the European Medicines Agency's advisory committee for Libtayo (cemiplimab) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation. This regulatory progress not only reflects favorable Phase 3 clinical trial results, but also points to potential expansion of Regeneron's oncology portfolio and commercial...",
    "url": "https://finance.yahoo.com/news/fda-ema-progress-libtayo-transforming-184147573.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "e5d28523-a799-3533-9e56-f82f1cf8f821",
      "content": {
        "id": "e5d28523-a799-3533-9e56-f82f1cf8f821",
        "contentType": "STORY",
        "title": "Is FDA and EMA Progress for Libtayo Transforming the Investment Story for Regeneron (REGN)?",
        "description": "",
        "summary": "Regeneron Pharmaceuticals recently received U.S. FDA approval and a positive opinion from the European Medicines Agency's advisory committee for Libtayo (cemiplimab) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation. This regulatory progress not only reflects favorable Phase 3 clinical trial results, but also points to potential expansion of Regeneron's oncology portfolio and commercial...",
        "pubDate": "2025-10-17T18:41:47Z",
        "displayTime": "2025-10-17T18:41:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w30LARiR1Z35GusfaFi.2g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3eDp_RSETU8kXm3usDK_gQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fda-ema-progress-libtayo-transforming-184147573.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-ema-progress-libtayo-transforming-184147573.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-17T11:30:00+00:00",
    "headline": "Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation",
    "summary": "Positive opinion based on results of Phase 3 C-POST trial that show Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p<0.0001), the primary endpoint of the trialTARRYTOWN, N.Y., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive",
    "url": "https://finance.yahoo.com/news/libtayo-cemiplimab-recommended-eu-approval-113000712.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "3e54afe8-4c89-343c-8322-c4a401fe1f44",
      "content": {
        "id": "3e54afe8-4c89-343c-8322-c4a401fe1f44",
        "contentType": "STORY",
        "title": "Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation",
        "description": "",
        "summary": "Positive opinion based on results of Phase 3 C-POST trial that show Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p<0.0001), the primary endpoint of the trialTARRYTOWN, N.Y., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive",
        "pubDate": "2025-10-17T11:30:00Z",
        "displayTime": "2025-10-17T11:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
          "originalWidth": 800,
          "originalHeight": 126,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ohIVokMiKClSVTQVwyB2lw--~B/aD0xMjY7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142.cf.webp",
              "width": 800,
              "height": 126,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YuYzNeQcIK6rRYN1HdT6UA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/libtayo-cemiplimab-recommended-eu-approval-113000712.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/libtayo-cemiplimab-recommended-eu-approval-113000712.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]